Azenta, Inc.

NasdaqGS:AZTA Stock Report

Market Cap: US$1.4b

Azenta Valuation

Is AZTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AZTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$32.94
Fair Value
10.8% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: AZTA ($29.37) is trading below our estimate of fair value ($32.94)

Significantly Below Fair Value: AZTA is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AZTA?

Key metric: As AZTA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AZTA. This is calculated by dividing AZTA's market cap by their current revenue.
What is AZTA's PS Ratio?
PS Ratio2x
SalesUS$668.82m
Market CapUS$1.35b

Price to Sales Ratio vs Peers

How does AZTA's PS Ratio compare to its peers?

The above table shows the PS ratio for AZTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.4x
TXG 10x Genomics
3x2.74%US$1.6b
FTRE Fortrea Holdings
0.4x0.98%US$1.0b
PSNL Personalis
9.2x27.97%US$680.2m
ADPT Adaptive Biotechnologies
8.9x13.64%US$2.4b
AZTA Azenta
2x1.06%US$1.4b

Price-To-Sales vs Peers: AZTA is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (5.4x).

Price to Sales Ratio vs Industry

How does AZTA's PS Ratio compare vs other companies in the US Life Sciences Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.4x0.98%US$1.02b
ATLN Atlantic International
0.3x7.12%US$159.95m
NOTV Inotiv
0.08x5.63%US$40.20m
SNCE Science 37 Holdings
0.6x17.47%US$34.67m
AZTA 2.0xIndustry Avg. 3.4xNo. of Companies10PS02.85.68.411.214+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AZTA is good value based on its Price-To-Sales Ratio (2x) compared to the US Life Sciences industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is AZTA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AZTA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio2.2x

Price-To-Sales vs Fair Ratio: AZTA is good value based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AZTA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$29.37
US$35.17
+19.74%
9.20%US$40.00US$30.00n/a6
Oct ’26US$31.58
US$33.00
+4.50%
11.07%US$40.00US$30.00n/a6
Sep ’26US$30.54
US$33.00
+8.06%
11.07%US$40.00US$30.00n/a6
Aug ’26US$32.34
US$34.00
+5.13%
11.00%US$40.00US$30.00n/a5
Jul ’26US$31.76
US$32.25
+1.54%
13.93%US$40.00US$29.00n/a4
Jun ’26US$26.72
US$41.60
+55.69%
45.98%US$79.00US$29.00n/a5
May ’26US$26.23
US$51.60
+96.72%
33.08%US$79.00US$30.00n/a5
Apr ’26US$34.12
US$53.25
+56.07%
6.42%US$59.00US$50.00n/a4
Mar ’26US$43.62
US$58.67
+34.49%
16.75%US$79.00US$50.00n/a6
Feb ’26US$54.05
US$59.00
+9.16%
17.97%US$79.00US$50.00n/a5
Jan ’26US$50.00
US$58.60
+17.20%
18.71%US$79.00US$48.00n/a5
Dec ’25US$46.21
US$56.60
+22.48%
20.19%US$79.00US$48.00n/a5
Nov ’25US$41.22
US$61.00
+47.99%
18.34%US$79.00US$50.00US$30.205
Oct ’25US$47.50
US$61.80
+30.11%
17.23%US$79.00US$50.00US$31.585
Sep ’25US$49.52
US$58.25
+17.63%
10.82%US$69.00US$53.00US$30.544
Aug ’25US$59.86
US$62.80
+4.91%
15.55%US$79.00US$53.00US$32.345
Jul ’25US$51.04
US$62.60
+22.65%
15.93%US$79.00US$52.00US$31.765
Jun ’25US$50.51
US$62.60
+23.94%
15.93%US$79.00US$52.00US$26.725
May ’25US$52.10
US$66.80
+28.21%
13.17%US$79.00US$56.00US$26.235
Apr ’25US$59.04
US$72.00
+21.95%
7.80%US$79.00US$64.00US$34.124
Mar ’25US$67.30
US$72.00
+6.98%
7.80%US$79.00US$64.00US$43.624
Feb ’25US$66.13
US$72.00
+8.88%
8.51%US$79.00US$63.00US$54.054
Jan ’25US$65.14
US$58.50
-10.19%
11.50%US$68.00US$50.00US$50.004
Dec ’24US$57.96
US$58.50
+0.93%
11.50%US$68.00US$50.00US$46.214
Nov ’24US$45.33
US$58.50
+29.05%
11.50%US$68.00US$50.00US$41.224
US$35.17
Fair Value
16.5% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/07 22:36
End of Day Share Price 2025/11/07 00:00
Earnings2025/06/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Azenta, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christopher MuseBarclays
Brett HodessBofA Global Research
Yuan ZhiB. Riley Securities, Inc.